NXE Nexgen Q1 loss widens to 053 with zero revenue as development costs climb shares fall 2 ARMP Armata Pharmaceuticals Inc falls 564 as drastically wider than expected Q4 2025 net loss spooks investors Why Research REFR deserves more attention from serious investors Trend Weakens 20260507